Literature DB >> 36055193

Modeling human multi-lineage heart field development with pluripotent stem cells.

Donghe Yang1, Juliana Gomez-Garcia2, Shunsuke Funakoshi3, Thinh Tran4, Ian Fernandes5, Gary D Bader6, Michael A Laflamme7, Gordon M Keller8.   

Abstract

The cardiomyocyte (CM) subtypes in the mammalian heart derive from distinct lineages known as the first heart field (FHF), the anterior second heart field (aSHF), and the posterior second heart field (pSHF) lineages that are specified during gastrulation. We modeled human heart field development from human pluripotent stem cells (hPSCs) by using single-cell RNA-sequencing to delineate lineage specification and progression. Analyses of hPSC-derived and mouse mesoderm transcriptomes enabled the identification of distinct human FHF, aSHF, and pSHF mesoderm subpopulations. Through staged manipulation of signaling pathways identified from transcriptomics, we generated myocyte populations that display molecular characteristics of key CM subtypes. The developmental trajectory of the human cardiac lineages recapitulated that of the mouse, demonstrating conserved cardiovascular programs. These findings establish a comprehensive landscape of human embryonic cardiogenesis that provides access to a broad spectrum of cardiomyocytes for modeling congenital heart diseases and chamber-specific cardiomyopathies as well as for developing new therapies to treat them.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac mesoderm specification; cardiomyocyte subtypes; hPSC models; human and mouse comparison; human heart field development; scRNA-seq

Mesh:

Year:  2022        PMID: 36055193     DOI: 10.1016/j.stem.2022.08.007

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   25.269


  1 in total

1.  Uncovering the origins and lineage markers of human heart fields.

Authors:  Matthew Miyamoto; Chulan Kwon
Journal:  Cell Stem Cell       Date:  2022-09-01       Impact factor: 25.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.